Ioduro (131i) De Sodio Curium Pharma Spain

Sodium Iodide (I‑131), the active ingredient in Ioduro (131i) De Sodio, is a radioactive iodine drug presented as an oral radiopharmaceutical for oral use. It selectively destroys thyroid tissue and thyroid cancer cells, and is employed in patients with thyroid malignancies, hyperthyroidism, or after thyroidectomy to eliminate residual tissue.

GNH USA supplies Ioduro (131i) De Sodio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across all markets, through robust quality‑assurance processes.

Sodium Iodide (I‑131) is a radioactive iodine agent used in thyroid‑related conditions. - Thyroid cancer: eliminates residual or metastatic thyroid cancer cells after surgery. - Hyperthyroidism (e.g., Graves disease): ablates overactive thyroid tissue to restore normal hormone levels. - Post‑thyroidectomy ablation: destroys remaining thyroid tissue to facilitate complete remission and simplify subsequent hormone replacement.

Sodium Iodide (I‑131) may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea or vomiting - Dry mouth and altered taste - Neck pain or tenderness - Sialadenitis (inflammation of salivary glands) - Transient leukopenia - Fatigue or mild weakness

Serious or Rare Side Effects: - Bone marrow suppression leading to pancytopenia - Severe radiation thyroiditis - Pulmonary fibrosis (radiation pneumonitis) - Secondary malignancies (e.g., leukemia) - Allergic reactions or anaphylaxis - Persistent hypothyroidism requiring lifelong hormone replacement

Before using Sodium Iodide (I‑131), several precautions should be observed to minimize risks. - Pregnancy status: confirm patient is not pregnant or assess risk‑benefit carefully. - Thyroid function: evaluate baseline thyroid hormone levels and adjust therapy accordingly. - Radiation safety: advise patient on minimizing radiation exposure to family and caregivers. - Hydration: ensure adequate fluid intake to promote renal clearance of radioiodine. - Blood counts: monitor complete blood count before and after treatment for hematologic effects. - Store at ambient temperature: keep in original container, protect from moisture and light.

Sodium Iodide (I‑131) can interact with other substances that affect iodine uptake or radiation response.

Major Interactions (Avoid): - Antithyroid drugs (e.g., methimazole, propylthiouracil): reduce iodine uptake and diminish therapeutic effect. - Lithium: increases retention of radioiodine in thyroid, raising radiation dose. - High‑iodine diet or iodine‑containing contrast agents: compete for uptake and lower efficacy.

Moderate Interactions (Monitor Closely): - Amiodarone: high iodine content may interfere with treatment; monitor thyroid function. - Diuretics (e.g., furosemide): may affect renal clearance of radioiodine. - Corticosteroids: may mask inflammatory responses; observe for delayed side effects.